Brought to you by 
Genzyme completes acquisition of AnorMed
14 Sep 2016
Executive Summary
Genzyme has agreed to acquire all outstanding AnorMed common shares for $584mm in cash, or $13.50 per share (about market average). In August, Genzyme offered to pay $380mm ($8.55 a share a 54% premium to market) for the company.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme completes acquisition of AnorMed
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice